STOCK TITAN
  1. Home
  2. News
  3. KNTE

Kinnate Biopharma Inc - KNTE STOCK NEWS

Welcome to our dedicated news page for Kinnate Biopharma (Ticker: KNTE), a resource for investors and traders seeking the latest updates and insights on Kinnate Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kinnate Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kinnate Biopharma's position in the market.

News
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
Rhea-AI Summary
Kinnate Biopharma Inc. (Nasdaq: KNTE) has entered into an Asset Purchase Agreement with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction aims to enhance Pierre Fabre's precision oncology efforts and expand targeted therapy options for patients with RAF and RAS solid tumors. Kinnate will receive up to $31 million in total consideration for the sale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
none
-
News
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
Rhea-AI Summary
Kinnate Biopharma Inc. (KNTE) has announced a definitive merger agreement with XOMA Corporation, where XOMA will acquire Kinnate for a price per share of between $2.3352 and $2.5879 in cash, with additional contingent value rights. The acquisition has been unanimously approved by Kinnate's Board of Directors and is expected to close in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.33%
Tags
acquisition
-
News
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Rhea-AI Summary
Kinnate Biopharma Inc. (Nasdaq: KNTE) reported promising exarafenib combination data in NRAS mutant melanoma and plans to advance its pan-RAF inhibitor, c-MET inhibitor KIN-8741, and CDK4 selective inhibitor program. The company also announced a strategic reprioritization and workforce restructuring, with $180.3 million in cash, cash equivalents, and investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
earnings
News
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
Rhea-AI Summary
Kinnate Biopharma announces pipeline updates and reprioritization plan, as well as a workforce restructuring
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
News
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Rhea-AI Summary
Kinnate Biopharma Inc. (KNTE) received FDA clearance for its brain-penetrant MEK inhibitor, KIN-7136, and expects to enter Phase 1 trial in the second half of 2023. The company has $204.3 million in cash, cash equivalents, and investments as of June 30, 2023, anticipated to fund operations into early 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
earnings
-
News
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
News
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
earnings
-
News
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
none
-
News
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
none
News
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.92%
Tags
earnings
Stock KNTE logo
Kinnate Biopharma Inc

Nasdaq:KNTE

KNTE Rankings

N/A Ranked by Market Cap
#5433 Ranked by Stock Gains
N/A Ranked by Dividends

KNTE Stock Data

124.99M
22.68M
0.16%
82.58%
0.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About KNTE

kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california.